DEFA14A: BioSig Adjourns Merger Shareholder Vote

BioSig Technologies announced the adjournment of a key shareholder vote for its Streamex merger due to pending Nasdaq approval, though the merger itself and company operations remain unaffected.

Summary

• BioSig Technologies, Inc. provided an update on its merger with Streamex Exchange Corporation.
• The merger transaction officially closed on May 28, 2025.
• 19.99% of BioSig shares are already issuable to Streamex shareholders.
• The issuance of the remaining shares is pending Nasdaq approval and formal stockholder approval.
• Proposal No. 1 (the Acquisition Proposal) for the September 5, 2025 Special Meeting will be adjourned to a later date.
• The adjournment is due to pending Nasdaq approval for the remaining share issuances.
• The adjournment does not impact the closing of the merger, the timing of company financings, or company operations.
• All other proposals for the September 5, 2025 Special Meeting will proceed as planned.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a procedural delay for shareholder approval, the core merger has closed, and the company explicitly states that operations and financings are not impacted. The delay is attributed to a regulatory approval process rather than a fundamental issue with the merger itself.

Positives

• The merger with Streamex Exchange Corporation officially closed on May 28, 2025.
• The adjournment of Proposal No. 1 does not impact the closing of the merger, the timing of company financings, or the operations of the company.
• 19.99% of BioSig shares are already issuable to Streamex shareholders.

Negatives

• Shareholder approval for the remaining share issuances related to the Streamex merger is still pending.
• Proposal No. 1 (the Acquisition Proposal) at the September 5, 2025 Special Meeting has been adjourned to a later, unannounced date.

Risks

• Uncertainty regarding the ability to realize the full benefits of the acquisition of Streamex.
• Risk that shareholder approval of the acquisition for the remaining shares may not be obtained.
• Potential inability to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise.
• General risks and uncertainties detailed in the Annual Report on Form 10-K filed with the SEC on April 15, 2025.

Future Outlook

The company aims to realize the benefits of the Streamex acquisition and obtain shareholder approval for the remaining share issuances, while maintaining compliance with Nasdaq's listing criteria.

Management Comments

• The Board of Directors has determined that, due to pending Nasdaq approval, Proposal No. 1 (the Acquisition Proposal) will not be acted upon at the September 5, 2025, Special Meeting and will instead be adjourned to a later date to be announced by the Company at the Special Meeting.
• Importantly, the removal of Proposal No. 1 from the proxy does not impact: The closing of the merger; The timing of closings of the Company's financings; or The operations of the Company.

Industry Context

BioSig, a medical device technology company, has merged with Streamex, an RWA tokenization company. This indicates a diversification strategy, potentially leveraging BioSig's public listing for Streamex's entry into the capital markets, bridging traditional medical tech with emerging blockchain/fintech sectors. The RWA tokenization market is a growing area within blockchain, aiming to bring real-world assets onto the blockchain.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a delay in voting on the full share issuance for the Streamex merger. Those expecting Streamex shares will have a delayed issuance for the majority of their entitlement.
• Management: Must manage the process of obtaining Nasdaq approval and rescheduling the shareholder meeting.
• Employees: Company operations are explicitly stated as not impacted.

Next Steps

• Announce a later date for the reconvened Special Meeting to act upon Proposal No. 1.
• Obtain formal stockholder approval for the issuance of the remaining shares related to the Streamex merger.
• Secure final Nasdaq approval for the remaining share issuances.

Key Dates

Recommendation

The merger has closed, which is a positive, but the delay in shareholder approval for the remaining share issuance and pending Nasdaq approval introduces a degree of uncertainty. While the company states operations and financings are unaffected, the market may react cautiously to any procedural delays in a significant transaction. A "hold" recommendation reflects waiting for the resolution of these approvals before making a more definitive investment decision, as the core business operations are stable but the full integration and share issuance are not yet complete.

Keywords

BioSig Technologies, Streamex Exchange, Merger, Acquisition, NASDAQ, Shareholder Vote, Proxy Statement, Medical Device, RWA Tokenization, Financial Technology, Cardiovascular Arrhythmias